Guangzhou Innogen Pharmaceutical Group Co., Ltd.
廣州銀諾醫藥集團股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2591)

(I) POLL RESULTS OF THE ANNUAL GENERAL MEETING AND (II) ABOLITION OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Reference is made to the notice (the "**AGM Notice**") of the annual general meeting (the "**AGM**") and the circular (the "**Circular**") of GUANGZHOU INNOGEN PHARMACEUTICAL GROUP CO., LTD. (the "**Company**") both dated 5 June 2026. Unless the context requires otherwise, terms used herein shall have the same meanings as those defined in the Circular.

(I) POLL RESULTS OF AGM

The Board is pleased to announce that the AGM was held at 21st Floor, Qiantan Times Square, 399 Haiyang West Road, Pudong New Area, Shanghai, the PRC on 29 June 2026 at 10:00 a.m., and the proposed resolutions (the "**Resolutions**") as set out in the AGM Notice were duly passed by the Shareholders by way of poll. The poll results in respect of the Resolutions are as follows:

Ordinary Resolutions		Number of votes (%)		
		For	**Against**	**Abstain**
1.	To consider and approve the 2025 Report of the Board.	257,493,057 (99.9988%)	0 (0.0000%)	3,000 (0.0012%)
2.	To consider and approve the 2025 Report of the Supervisory Committee.	257,493,057 (99.9988%)	0 (0.0000%)	3,000 (0.0012%)
3.	To consider and approve the 2025 Audited Consolidated Financial Statements.	257,493,057 (99.9988%)	0 (0.0000%)	3,000 (0.0012%)
4.	To consider and approve the 2025 Annual Report.	257,493,057 (99.9988%)	0 (0.0000%)	3,000 (0.0012%)

Ordinary Resolutions		Number of votes (%)		
		For	Against	Abstain
5.	To consider and approve the profit distribution plan for the year ended 31 December 2025.	257,493,057 (99.9988%)	0 (0.0000%)	3,000 (0.0012%)
6.	To consider and approve the re-appointment of Ernst & Young as the financial report auditor of the Company for 2026, to hold office until the conclusion of the next annual general meeting of the Company, and to authorise the Board to fix the remuneration of the auditor.	253,873,044 (98.5930%)	0 (0.0000%)	3,623,013 (1.4070%)
7.	To consider and approve the re-election and remuneration of Dr. WANG QINGHUA as an executive Director.	253,873,044 (98.5930%)	0 (0.0000%)	3,623,013 (1.4070%)
8.	To consider and approve the re-election and remuneration of Ms. Jiang Fan as an executive Director.	253,873,044 (98.5930%)	0 (0.0000%)	3,623,013 (1.4070%)
9.	To consider and approve the re-election and remuneration of Ms. Xu Wenjie as an executive Director.	253,873,044 (98.5930%)	0 (0.0000%)	3,623,013 (1.4070%)
10.	To consider and approve the re-election and remuneration of Mr. Huang Bing as an executive Director.	253,873,044 (98.5930%)	0 (0.0000%)	3,623,013 (1.4070%)
11.	To consider and approve the re-election and remuneration of Mr. HO KYUNG SHIK as a non-executive Director.	253,873,044 (98.5930%)	0 (0.0000%)	3,623,013 (1.4070%)
12.	To consider and approve the re-election and remuneration of Mr. Heng Lei as a non-executive Director.	253,873,044 (98.5930%)	0 (0.0000%)	3,623,013 (1.4070%)

Ordinary Resolutions		Number of votes (%)		
		For	Against	Abstain
13.	To consider and approve the re-election and remuneration of Mr. Tao Wuping as an independent non-executive Director.	253,872,935 (98.5929%)	109 (0.0000%)	3,623,013 (1.4070%)
14.	To consider and approve the re-election and remuneration of Dr. Song Ruilin as an independent non-executive Director.	253,873,044 (98.5930%)	0 (0.0000%)	3,623,013 (1.4070%)
15.	To consider and approve the re-election and remuneration of Mr. Chan Heung Wing Anthony as an independent non-executive Director.	253,873,044 (98.5930%)	0 (0.0000%)	3,623,013 (1.4070%)
Special Resolutions		**Number of votes (%)**		
		For	**Against**	**Abstain**
16.	To consider and approve the abolishment of the supervisory committee of the Company.	253,873,044 (98.5930%)	0 (0.0000%)	3,623,013 (1.4070%)
17.	To consider and approve the proposed amendments to the Articles of Association, including amending the business scope of the Company and name change of the promoters of the Company, and handling of registration matters.	253,873,044 (98.5930%)	0 (0.0000%)	3,623,013 (1.4070%)
18.	To consider and approve the proposed amendments to the Rules of Procedures for the General Meeting.	253,873,044 (98.5930%)	0 (0.0000%)	3,623,013 (1.4070%)
19.	To consider and approve the proposed amendments to the Rules of Procedures for the Board of Directors.	253,873,044 (98.5930%)	0 (0.0000%)	3,623,013 (1.4070%)

Special Resolutions		Number of votes (%)		
		For	Against	Abstain
20.	To consider and approve the grant of a general mandate to the Directors to repurchase H Shares in issue on the Stock Exchange with an aggregate nominal value not exceeding 10% of the aggregate nominal value of H Shares (excluding treasury shares) in issue as at the date of passing of this resolution.	253,873,044 (98.5930%)	0 (0.0000%)	3,623,013 (1.4070%)
21.	To consider and approve the grant of a general mandate to the Directors to allot, issue and deal with H Shares not exceeding 20% of the H Shares (excluding treasury shares) in issue as at the date of passing of this resolution.	171,986,104 (66.7917%)	81,886,940 (31.8012%)	3,623,013 (1.4070%)
22.	To consider and approve proposed adoption of the Share Award Scheme.	171,986,096 (66.7917%)	81,886,940 (31.8012%)	3,623,021 (1.4070%)
23.	To consider and approve the proposed authorisation to the Board and/or its authorised persons to deal with matters pertaining to the Share Award Scheme.	213,717,660 (82.9984%)	40,155,384 (15.5946%)	3,623,013 (1.4070%)
24.	To consider and approve (subject to the passing of resolution No. 22) a sublimit for service providers of 4,568,193 Shares, representing approximately 1% of the total issued Shares (excluding treasury shares) as at the date of adoption of the Share Award Scheme.	171,986,104 (66.7917%)	40,155,384 (15.5946%)	45,354,569 (17.6137%)

As more than 50% of the votes attaching to the Shares held by the Shareholders present and voting in person or by proxy at the AGM were cast in favour of each of resolutions numbered 1 to 15 above, all such ordinary resolutions were duly passed.

As at least two-thirds of the votes attaching to the Shares held by the Shareholders present and voting in person or by proxy at the AGM were cast in favour of each of resolutions numbered 16 to 24 above, all such special resolutions were duly passed.

As at the date of the AGM, the total number of issued Shares was 456,819,349 Shares, which was the total number of Shares entitling the holders to attend and vote on all the Resolutions at the AGM. There were no Shareholders who were entitled to attend and abstain from voting in favour of any of the Resolutions at the AGM according to Rule 13.40 of the Listing Rules and there were no Shareholders who were required under the Listing Rules to abstain from voting at the AGM. There were no Shares entitling the Shareholders to attend and vote only against any of the Resolutions at the AGM.

None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on the Resolutions at the AGM.

The Company appointed Tricor Investor Services Limited (the Company's H Share registrar), a supervisor of the Company and two representatives from the Shareholders to act jointly as the scrutineers for the vote-taking at the AGM.

All Directors (including Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors) attended the AGM.

(II) ABOLITION OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

References are made to the announcement of the Company dated 1 June 2026 and the Circular in relation to, among others, the proposed abolition of the Supervisory Committee and the proposed amendments to the Articles of Association. The Board announces that the abolition of the Supervisory Committee and the proposed amendments to the Articles of Association were approved by the Shareholders at the AGM. Accordingly, the Company has abolished the Supervisory Committee with effective from 29 June 2026 and the relevant corporate governance systems of the Supervisory Committee will be repealed simultaneously. Mr. Yue Jianjun, Dr. Li Yuanpeng and Ms. Shao Anna ceased to serve as the Supervisors. Each of the Supervisors has confirmed that he/she has no disagreement with the Board and Supervisory Committee, and that there is no other matter in relation to his/her cessation of office as a Supervisor that needs to be brought to the attention of the Shareholders.

The Company would like to express heartfelt gratitude to all the Supervisors for their contributions to the Company during their tenure.

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the PRC, 29 June 2026

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.